A Phase 3 clinical trial evaluating BeiGene’s (NASDAQ:BGNE) PD-1 inhibitor tislelizumab, combined with two chemo regimens, for the first-line treatment of patients with squamous non-small cell lung cancer (NSCLC) met the primary endpoint of progression-free survival (PFS) at the planned interim analysis.
Additional data will be submitted for presentation at an upcoming medical conference.
The company plans to file a supplemental marketing application in China.
The China National Medical Products Administration approved tislelizumab last month for Hodgkin lymphoma patients who have received at least two prior lines of therapy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.